11/21
05:31 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/21
05:31 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/20
01:50 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/19
06:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/14
12:33 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/14
12:33 pm
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/14
11:56 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/14
11:56 am
trvi
Rating for TRVI
Low
Report
Rating for TRVI
11/14
09:14 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/14
09:05 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/14
09:05 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/13
09:53 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.